3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2011 Thrombin expression in prostate: a novel finding Cancer Invest. 2011 Jan; 29(1):62-7. PMID:21166500. DOI:10.3109/07357907.2010.535057
2. 2011 Novel Molecular Targets of Azadirachta indica Associated with Inhibition of Tumor Growth in Prostate Cancer AAPS J. 2011 May 11. [Epub ahead of print] PMID:21560017. DOI:10.1208/s12248-011-9279-4.
3. 2011 Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8. PMID:21558995.
4. 2010 New developments in the medical management of prostate cancer Mayo Clin Proc. 2010 Jan; 85(1):77-86. PMID:20042563. PMCID:2800284. DOI:10.4065/mcp.2009.0442.
5. 2010 Multiple urinary bladder masses from metastatic prostate adenocarcinoma Rare Tumors. 2010; 2(4):186-188. DOI:10.4081/rt.2010e65.
6. 2010 Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8. PMID:21178268. DOI:10.3233/CBM-2010-0152.
7. 2010 Hormonal Therapy in Prostate Cancer Encyclopedia of Cancer 3rd ed. 2010. (Book chapter)
8. 2010 Endocrine Manipulations CANCER: Principles and Practice of Oncology 2010. (Book chapter)
9. 2009 Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4. PMID:19219655. DOI:10.1080/07357900802527247.
10. 2008 Expression of tissue factor in prostate cancer correlates with malignant phenotype Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6. PMID:18091328. DOI:10.1097/01.pai.0000213157.94804.fc.
11. 2006 Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58. PMID:17264396.
12. 2006 Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
13. 2006 Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800. PMID:16834663. DOI:10.1111/j.1442-2042.2006.01405.x.
14. 2006 Management of solitary palatal metastasis from renal cell carcinoma Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396. PMID:16835627. DOI:10.1038/ncpuro0536
15. 2006 Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7. PMID:17099632.
16. 2005 Stage specific expression of VEGF A and D in prostate cancer Clin Cancer Res. 2005; 11:1-10.
17. 2005 Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21
18. 2005 Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma J Clin Oncol. 2005 Sep 1; 23(25):6267-8.
19. 2005 Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage Clin Prostate Cancer. 2005 Sep; 4(2):134-7. PMID:16197616.
20. 2005 Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May; 3(5):425-7. PMID:16167017
21. 2004 The academic hematology-oncology firm: a model for postgraduate cancer education J Cancer Educ. 2004 Spr; 19(1):45-9. PMID:15059755.
22. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20
23. 2004 COX-2: an inconsistent therapeutic target in prostate cancer Uro Oncology. 2004 Sept/Dec; 4(3/4):113-8.
24. 2003 Role of coagulation and fibrinolytic system in prostate cancer Semin Thromb Hemost. 2003 Jun; 29(3):301-8. PMID:12888934
25. 2003 Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer Urology. 2003 Apr; 61(4):765-9. PMID:12670562.
26. 2003 Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58. PMID:12699077
27. 2003 Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445. PMID:12805351.
28. 2002 Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5. PMID:11994561
29. 2002 Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3. PMID:12089240.
30. 2000 Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71. PMID:10832943
31. 1999 Impact of nutrition on the age related declines in heamatopoiesis Chernoff R. Geriatric nutrition the health professional’s handbook. 2nd ed. Aspen: Jones & Bartlett Publishers; 1999. (Book chapter)

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.